20.500.12556/DiRROS-15410 Availability and costs of medicines for the treatment of tuberculosis in Europe Cost of TB in Europe Objectives. To evaluate the access to comprehensive diagnostics and novel anti-tuberculosis medicines in European countries. Methods. We investigated access to genotypic and phenotypic M. tuberculosis drug susceptibility testing, availability of anti-tuberculosis drugs and calculated cost of drugs and treatment regimens at major tuberculosis treatment centers in countries of the World Health Organization (WHO) European region where rates of drug-resistant tuberculosis are highest among all WHO regions. Results are stratified by middle-income and high-income countries. Results. Overall, 43 treatment centers in 43 countries participated in the study. For WHO Group A drugs, the frequency of countries with availability of phenotypic drug susceptibility testing was as follows: 30/40 (75%) for levofloxacin, 33/40 (82%) for moxifloxacin, 19/40 (48%) for bedaquiline and 29/40 (72%) for linezolid, respectively. Overall, 36/43 (84%) and 24/43 (56%) of countries had access to bedaquiline and delamanid, while only 6/43 (14%) had access to rifapentine. Treatment of patients with extensively drug-resistant tuberculosis with a regimen including a carbapenem was only available in 17/43 (40%) of the countries. Median cost of regimens for drug-susceptible tuberculosis, multidrug-resistant/rifampicin-resistant tuberculosis (shorter regimen, including bedaquiline for six months) and extensively drug-resistant tuberculosis (including bedaquiline, delamanid and a carbapenem) were € 44 (min-max € 15-152), € 764 (min-max € 542-15152) and € 8709 (min-max € 7965-11759) in middle-income countries (n=12), and € 280 (min-max-€78-1084), € 29765 (min-max 11116-40584), € 217591 (min-max € 82827-320146) in high-income countries (n=29). Conclusion. In countries of the WHO Europe Region there is a widespread lack of drug susceptibility testing capacity to new and re-purposed anti-tuberculosis drugs, lack of access to essential medications in several countries and high treatment cost for drug-resistant tuberculosis. tuberculosis - drug therapy Mycobacterium tuberculosis - drug therapy health care costs - drug therapy Europe tuberkuloza - terapija z zdravili Mycobacterium tuberculosis - terapija z zdravili stroški zdravstvene oskrbe - terapija z zdravili Evropa true false true Elsevier Angleški jezik Ni določen Europe; Evropa © 2022 The Author(s). Neznano 2022-08-31 14:50:11 2022-08-31 14:50:11 2022-09-01 03:34:39 0000-00-00 00:00:00 2022 0 Velika Britanija 0 Nasl. z nasl. zaslona; Članica raziskovalne skupine TBNET iz Slovenije: Petra Svetina; Opis vira z dne 24. 8. 2022; str. 1-29 št. Vol. 28 2022 0000-00-00 NiDoloceno NiDoloceno NiDoloceno 0000-00-00 2022-07-28 2022-08-09 616-002 1469-0691 10.1016/j.cmi.2022.07.026 119066371 https://www.clinicalmicrobiologyandinfection.com/action/showPdf?pii=S1198-743X%2822%2900394-9 1 7682a517-292b-11ed-b6b8-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=20367 Univerzitetna klinika za pljučne bolezni in alergijo Golnik 0 0 0